CE-MRA in the Age of Nephrogenic Systemic Fibrosis

  • Aditya Bharatha
  • Sean P. Symons
  • Walter Kucharczyk


The purpose of this chapter is to review the current knowledge concerning nephrogenic systemic fibrosis (NSF) and discuss its implications for contrast-enhanced MR angiography (MRA). NSF is a rare but serious systemic fibrosing condition occurring in patients with profound renal impairment. An increasing body of literature has implicated gadolinium (Gd)-based MR contrast agents (GBCAs) as the causative factor in the development of NSF. We discuss the clinical aspects of the disease, review the literature supporting an etiologic role of GBCAs, discuss risk factors for the disease, and cover current recommendations and prevention strategies with particular emphasis on MRA applications.


Acute Renal Failure Nephrogenic Systemic Fibrosis Gadopentetate Dimeglumine Gadobenate Dimeglumine Severe Renal Dysfunction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    LeBoit PE. What nephrogenic fibrosing dermopathy might be. Arch Dermatol. 2003;139:928–930.PubMedCrossRefGoogle Scholar
  2. 2.
    Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000–1001.PubMedCrossRefGoogle Scholar
  3. 3.
    Mayr M, Burkhalter F, Bongartz G. Nephrogenic systemic fibrosis: clinical spectrum of disease. J Magn Reson Imaging. 2009;30:1289–1297.PubMedCrossRefGoogle Scholar
  4. 4.
    Jimenez SA, Artlett CM, Sandorfi N, et al. Dialysis associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50:2660–2666.PubMedCrossRefGoogle Scholar
  5. 5.
    Juluru K, Vogel-Claussen J, Macura KJ, Kamel IR, Steever A, Bluemke DA. MR imaging in patients at risk for developing nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics. 2009;29:9–22.PubMedCrossRefGoogle Scholar
  6. 6.
    Prince MR, Zhang HL, Prowda JC, Grossman ME, Silvers DN. Nephrogenic systemic fibrosis and its impact on abdominal imaging. Radiographics. 2009;29:1565–1574.PubMedCrossRefGoogle Scholar
  7. 7.
    Grobner T. Gadolinium – a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant. 2006;21:1104–1108.PubMedCrossRefGoogle Scholar
  8. 8.
    High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:21–26.PubMedCrossRefGoogle Scholar
  9. 9.
    Wiginton CD, Kelly B, Oto A, et al. Gadoliniumbased contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. AJR Am J Roentgenol. 2008;190:1060–1068.PubMedCrossRefGoogle Scholar
  10. 10.
    Weinreb JC, Abu-Alfa AK. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned? J Magn Reson Imaging. 2009;30:1236–1239.PubMedCrossRefGoogle Scholar
  11. 11.
    Idée JM, Port M, Robic C, Medina C, Sabatou M, Corot C.Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging. 2009;30:1249–1258.PubMedCrossRefGoogle Scholar
  12. 12.
    Aime S, Caravan P. Biodistribution of Gadolinium-based contrast agents, including gadolinium deposition. J Magn Reson Imaging. 2009;30:1259–1267.PubMedCrossRefGoogle Scholar
  13. 13.
    Leiner T, Kucharczyk W. NSF prevention in clinical practice: summary of recommendations and guidelines in the United States, Canada, and Europe. J Magn Reson Imaging. 2009;30:1357–1363.PubMedCrossRefGoogle Scholar
  14. 14.
    Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164–2173.PubMedCrossRefGoogle Scholar
  15. 15.
    Sieber MA, Steger-Hartmann T, Lengsfeld P, Pietsch H. Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging. 2009;30:1268–1276.PubMedCrossRefGoogle Scholar
  16. 16.
    Varani J, DaSilva M, Warner RL, Deming MO, Barron AG, Johnson KJ, Swartz RD. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol. 2009;44:74–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Newon BB, Jimenez SA. Mechanism of NSF: New evidence ­challenging the prevailing theory. J Magn Reson Imaging. 2009;30:1277–1283.CrossRefGoogle Scholar
  18. 18.
    Prince MR, Zhang HL, Roditi GH et al. Risk factors of NSF: a ­literature review. J Magn Reson Imaging. 2009;30:1298–1308.PubMedCrossRefGoogle Scholar
  19. 19.
    Bryant BJ 2nd, Im K, Broome DR. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clin Radiol. 2009;64:706–713.PubMedCrossRefGoogle Scholar
  20. 20.
    United States Food and Drug Administration. Information for Healthcare Professionals Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). Washington, D.C. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142884.htm. Accessed March 22, 2010.
  21. 21.
    American College of Radiology (ACR). Manual on Contrast Media, 6.0 edition. American College of Radiology; 2008:54–56. www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx. Accessed March 22, 2010.
  22. 22.
    Padilla-Thornton A, Rafat Zand K, Barrett B, Stein L, Andrew G, Forster BB. Canadian Association of Radiologists national advisory on gadolinium administration and nephrogenic systemic fibrosis. Can Assoc Radiol J. 2008;59:237–240.PubMedGoogle Scholar
  23. 23.
    European Society of Urogenital Radiology. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Vienna, Austria. http://www.esur.org/Nephrogenic_Fibrosis.39.0.html. Accessed March 22, 2010.
  24. 24.
    Miki Y, Isoda H, Togashi K. Guideline to use gadolinium-based contrast agents at Kyoto University Hospital. J Magn Reson Imaging. 2009;30:1364–1365.PubMedCrossRefGoogle Scholar
  25. 25.
    Laurent S, Elst LV, Muller RN. Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging. 2006;1:128–137.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Aditya Bharatha
    • 1
  • Sean P. Symons
    • 2
  • Walter Kucharczyk
    • 1
  1. 1.Department of Medical ImagingUniversity Health NetworkTorontoCanada
  2. 2.Sunnybrook Health Sciences CentreTorontoCanada

Personalised recommendations